Europe Immunosuppressant Drugs Market 2019-2028

MARKET OUTLOOK

This report has determined the immunosuppressant drugs market in Europe to proliferate at a compound annual growth rate of 3.88% during the forecast period 2019-2028.
Russia, Germany, Italy, Spain, France, the UK, and Rest of Europe together form the market in this region.

Close to 5 million people in France are affected by autoimmune diseases. They are the third most common category of disease in industrialized nations, after cancer and heart disease, in terms of morbidity and mortality. At present, there are treatments available to decelerate the progression of autoimmune diseases; however, there is no cure. Immunosuppressants form one of the treatment methods for these diseases. The growth in the prevalence of autoimmune diseases, in turn, raises the demand for immunosuppressants. And this is aiding the growth of the French immunosuppressant drugs market over the forecast period.

In Germany, renal transplants are the most common type of organ transplantation procedure, which is followed by liver and lung transplants. In 2018, 27.8 renal transplantation procedures per million population were performed in the country. The German Foundation of Organ Transplantation (DSO) states that, the one-time expenditure for renal transplantation is around 50,000 Euros, along with a maintenance cost of 12,000-14,000 Euros. Immunosuppressant (IS) drugs account for about 70% of the direct follow-up expenditure. Thus, an increase in the number of organ transplants increases the demand for immunosuppressant drugs in the country. This is proliferating the growth of the German immunosuppressant drugs market.

COMPETITIVE OUTLOOK

The competitive players in this market are Intas Pharmaceuticals Ltd (Accord Healthcare), Allergan (acquired by Abbvie Inc), Dr Reddys Laboratories Ltd, Pfizer Inc, Sanofi, Abbvie Inc, Cipla Ltd, and GlaxoSmithKline plc.

1. Europe Immunosuppressant Drugs Market - Summary

2. Industry Outlook

2.1. Market Definition
2.2. Key Insights
2.2.1. Organ Transplantation Leads the Market by End-User
2.2.2. Pharmaceutical Industry Showing Growth Trends
2.2.3. Impact of Covid-19 on Transplant Recipients
2.3. Evolution & Transition of Immunosuppressant Drugs
2.4. Porter's Five Force Analysis
2.4.1. Threat of New Entrants
2.4.2. Threat of Substitute
2.4.3. Bargaining Power of Suppliers
2.4.4. Bargaining Power of Buyers
2.4.5. Threat of Competitive Rivalry
2.5. Market Attractiveness Index
2.6. Vendor Scorecard
2.7. Market Drivers
2.7.1. Demand from Organ Transplantation
2.7.2. Rise in the Number of Autoimmune Disorders
2.8. Market Restraints
2.8.1. Side Effects of Immunosuppressant Drugs
2.9. Market Opportunities
2.9.1. Demand from Emerging Economies
2.9.2. Exports of Drugs and Medicine Worldwide on Rise
2.10. Market Challenges
2.10.1. Lack of Awareness About Organ Donation

3. Europe Immunosuppressant Drugs Market Outlook – by Drug Class

3.1. Corticosteroids
3.2. Monoclonal Antibodies
3.3. Calcineurin Inhibitors
3.4. Mtor Inhibitors
3.5. Others

4. Europe Immunosuppressant Drugs Market Outlook - by Distribution Channel

4.1. Hospital Pharmacies
4.2. Retail Pharmacies
4.3. Online Pharmacies

5. Europe Immunosuppressant Drugs Market Outlook - by End-User

5.1. Organ Transplantation
5.2. Autoimmune Disorders
5.3. Others

6. Europe Immunosuppressant Drugs Market – Regional Outlook

6.1. United Kingdom
6.2. Germany
6.3. France
6.4. Spain
6.5. Italy
6.6. Russia
6.7. Rest of Europe

7. Competitive Landscape

7.1. Abbvie Inc
7.2. Allergan (Acquired by Abbvie Inc)
7.3. Astellas Pharma Inc
7.4. Bristol-Myers Squibb Company
7.5. Cipla Ltd
7.6. Dr Reddys Laboratories Ltd
7.7. F Hoffmann-La Roche Ltd
7.8. GlaxoSmithKline plc
7.9. Intas Pharmaceuticals Ltd (Accord Healthcare)
7.10. Janssen Pharmaceuticals Inc (Johnson & Johnson Services Inc)
7.11. Mylan Nv
7.12. Novartis AG
7.13. Pfizer Inc
7.14. Sanofi
7.15. Veloxis Pharmaceuticals Inc

8. Methodology & Scope

8.1. Research Scope
8.2. Sources of Data
8.3. Research Methodology

List of Tables

Table 1: Europe Immunosuppressant Drugs Market, by Country, 2019-2028 (In $ Million)
Table 2: Market Attractiveness Index
Table 3: Vendor Scorecard
Table 4: Side-Effects of Immunosuppressant Drugs
Table 5: Top 15 Positive Net Exports Countries and Negative Net Exports for Drugs & Medicines Countries
Table 6: Europe Immunosuppressant Drugs Market, by Drug Class, 2019-2028 (In $ Million)
Table 7: Europe Immunosuppressant Drugs Market, by Distribution Channel, 2019-2028 (In $ Million)
Table 8: Europe Immunosuppressant Drugs Market, by End-User, 2019-2028 (In $ Million)

List of Figures

Figure 1: Evolution & Transition of Immunosuppressant Drugs
Figure 2: Porter's Five Force Analysis
Figure 3: Europe Immunosuppressant Drugs Market, by Corticosteroids, 2019-2028 (In $ Million)
Figure 4: Europe Immunosuppressant Drugs Market, by Monoclonal Antibodies, 2019-2028 (In $ Million)
Figure 5: Europe Immunosuppressant Drugs Market, by Calcineurin Inhibitors, 2019-2028 (In $ Million)
Figure 6: Europe Immunosuppressant Drugs Market, by Mtor Inhibitors, 2019-2028 (In $ Million)
Figure 7: Europe Immunosuppressant Drugs Market, by Others, 2019-2028 (In $ Million)
Figure 8: Europe Immunosuppressant Drugs Market, by Hospital Pharmacies, 2019-2028 (In $ Million)
Figure 9: Europe Immunosuppressant Drugs Market, by Retail Pharmacies, 2019-2028 (In $ Million)
Figure 10: Europe Immunosuppressant Drugs Market, by Online Pharmacies, 2019-2028 (In $ Million)
Figure 11: Europe Immunosuppressant Drugs Market, by Organ Transplantation, 2019-2028 (In $ Million)
Figure 12: Europe Immunosuppressant Drugs Market, by Autoimmune Disorders, 2019-2028 (In $ Million)
Figure 13: Europe Immunosuppressant Drugs Market, by Others, 2019-2028 (In $ Million)
Figure 14: Europe Immunosuppressant Drugs Market, Regional Outlook, 2019 & 2028 (In %)
Figure 15: United Kingdom Immunosuppressant Drugs Market, 2019-2028 (In $ Million)
Figure 16: Germany Immunosuppressant Drugs Market, 2019-2028 (In $ Million)
Figure 17: France Immunosuppressant Drugs Market, 2019-2028 (In $ Million)
Figure 18: Spain Immunosuppressant Drugs Market, 2019-2028 (In $ Million)
Figure 19: Italy Immunosuppressant Drugs Market, 2019-2028 (In $ Million)
Figure 20: Russia Immunosuppressant Drugs Market, 2019-2028 (In $ Million)
Figure 21: Rest of Europe Immunosuppressant Drugs Market, 2019-2028 (In $ Million)